Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Medtronic

Last Updated: March 26, 2023

Tecovirimat - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for tecovirimat and what is the scope of freedom to operate?

Tecovirimat is the generic ingredient in one branded drug marketed by Siga Technologies and is included in two NDAs. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tecovirimat has ninety-three patent family members in twenty-two countries.

One supplier is listed for this compound.

Summary for tecovirimat
International Patents:93
US Patents:9
Tradenames:1
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 24
Clinical Trials: 10
Patent Applications: 127
DailyMed Link:tecovirimat at DailyMed
Recent Clinical Trials for tecovirimat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Calmy AlexandraPhase 3
Oswaldo Cruz FoundationPhase 3
ANRS, Emerging Infectious DiseasesPhase 3

See all tecovirimat clinical trials

US Patents and Regulatory Information for tecovirimat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Siga Technologies TPOXX tecovirimat SOLUTION;INTRAVENOUS 214518-001 May 18, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Siga Technologies TPOXX tecovirimat CAPSULE;ORAL 208627-001 Jul 13, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Siga Technologies TPOXX tecovirimat SOLUTION;INTRAVENOUS 214518-001 May 18, 2022 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for tecovirimat

Country Patent Number Title Estimated Expiration
Canada 2866037 PRODUITS CHIMIQUES, COMPOSITIONS ET PROCEDES DE TRAITEMENT ET DE PREVENTION DES INFECTIONS A ORTHOPOXVIRUS ET DES MALADIES ASSOCIEES (CHEMICALS, COMPOSTIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORT HOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES) See Plans and Pricing
South Korea 20130135836 ST-246 LIQUID FORMULATIONS AND METHODS See Plans and Pricing
China 105111131 Polymorphic forms of ST-246 and methods of preparation See Plans and Pricing
Israel 224430 Liquid pharmaceutical formulation comprising st-246 and a beta-cyclodextrin, a process of making the liquid formulation, a unit dosage liquid formulation and a process for preparing a water-soluble solid st-246 pharmaceutical formulation See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for tecovirimat

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1638938 301177 Netherlands See Plans and Pricing PRODUCT NAME: TECOVIRIMAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1600/001 20220107
1638938 122022000032 Germany See Plans and Pricing PRODUCT NAME: TECOVIRIMAT ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1600 20220106
1638938 2290024-5 Sweden See Plans and Pricing PRODUCT NAME: TECOVIRIMAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1600/001 20220107
1638938 2022C/521 Belgium See Plans and Pricing PRODUCT NAME: TECOVIRIMAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1600 20220107
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKesson
McKinsey
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.